戻る Agenda
Session 5B: Health Canada Policy Activities and Transparency Updates
Session Chair(s)
Karen Feltmate
President
Redstone Health Group, Inc., Canada
This session provides an opportunity for Health Canada to provide an update on key policy and regulatory activities. The department has a number of priorities which fall under its mandate, a few of which were discussed by senior government officials during the opening plenaries. This session delves deeper into additional policy and regulatory issues being led by the department. Leaders within the Health Products and Food Branch will provide timely updates on these initiatives, including outlining the policy objectives, the specific actions being implemented, and the applicable timelines. Whether you are in academia, industry, a not-for-profit, or a regulator, this information will help build your overall knowledge of issues affecting your work and the broader Canadian population as a whole.
Speaker(s)
Update on Premarket Transparency Initiatives for Drugs and Medical Devices
Laura Johnson
Health Canada, Canada
Project Manager
Anti-Microbial Resistance: An Overview of Health Canada's Activities
Lucye Galand, DVM, MBA, MSc
Health Canada, Canada
Acting Director, BGIVD, Therapeutic Products Directorate, HPFB
Regulatory Foresight: Anticipating the Health Needs of Canadians
Celia Lourenco, PhD
Health Canada, Canada
Director General, Biologic and Radiopharmaceutical Drugs Directorate, HPFB
Elizabeth Toller, MA
Health Canada, Canada
Associate Director General, Policy, Planning and International Affairs Directora